Economic impact of severe and non-severe hypoglycemia in patients with Type 1 and Type 2 diabetes in the United States

被引：92

作者：

Foos, Volker ^{[1
]}

Varol, Nebibe ^{[2
]}

Curtis, Bradley H. ^{[3
]}

Boye, Kristina S. ^{[3
]}

Grant, David ^{[4
]}

Palmer, James L. ^{[1
]}

McEwan, Phil ^{[5
]}

机构：

[1] IMS Hlth, HEOR, Basel, Switzerland

[2] Eli Lilly & Co, Surrey, England

[3] Eli Lilly & Co, Indianapolis, IN 46285 USA

[4] IMS Hlth, HEOR, London, England

[5] Swansea Univ, Ctr Hlth Econ, Swansea, W Glam, Wales

来源：

JOURNAL OF MEDICAL ECONOMICS | 2015年 / 18卷 / 06期

关键词：

Episode costs; Health-economic-evaluation; Hypoglycemia; Medical resources; Type; 1; diabetes; 2;

D O I：

10.3111/13696998.2015.1006730

中图分类号：

F [经济];

学科分类号：

020101 [政治经济学];

摘要：

Objective: To identify the direct and indirect costs of hypoglycemia in patients with Type 1 or Type 2 diabetes mellitus (DM) in the US setting. Methods: A literature review was conducted to identify and review studies that reported data on the economic burden of hypoglycemia and the related medical resource consumption or productivity loss related to hypoglycemia in patients with Type 1 or Type 2 DM. Relevant information was collated in an economic model to assess the direct and indirect costs following severe and non-severe hypoglycemic events in Type 1 and Type 2 DM. Results: Detailed evidence of the medical cost burden of hypoglycemic events was identified from 14 studies. For both Type 1 and Type 2 DM, episodes requiring assistance from a healthcare practitioner were identified as particularly costly and amounted to $1161 per episode (direct costs) compared with episode costs of $66 and $11 for events requiring third-party (non-medical) assistance and events managed by self-treatment, respectively. Indirect costs associated with severe hypoglycemia requiring non-medical assistance, severe hypoglycemia requiring medical assistance, and non-severe hypoglycemia were predicted to be $242, $160, and $11 for patients with Type 1 diabetes and $579, $176, and $11 for patients with Type 2 diabetes, respectively. Conclusion: Both severe and non-severe hypoglycemia incur substantial healthcare costs. Failure to account for these costs may under-estimate the value of management strategies that minimize hypoglycemia risk.

引用

页码：420 / 432

页数：13

共 38 条

[1]

Standards of medical care in diabetes 2011, Diabetes Care, 34, 1, pp. 11-61, (2011)

[2]

Cryer P.E., Hypoglycemia: Still the limiting factor in the glycemic management of diabetes, Endocr Pract, 14, pp. 750-756, (2008)

[3]

Marrett E., Radican L., Davies M.J., Et al., Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: A survey study, BMC Res Notes, 4, (2011)

[4]

Gerstein H.C., Miller M.E., Et al., Long-term effects of intensive glucose lowering on cardiovascular outcomes, N Engl J Med, 364, pp. 818-828, (2011)

[5]

Risk of hypoglycemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration, Diabetologia, 50, pp. 1140-1147, (2007)

[6]

Brod M., Christensen T., Thomsen T.L., Et al., The impact of non-severe hypoglycemic events on work productivity and diabetes management, Value Health, 14, pp. 665-671, (2011)

[7]

Tahrani A., Barnett A.H., Brod M., Et al., Global survey finds three quarters of patients experience hypoglycemia on insulin analogue causing dose irregularities and increased blood-glucose monitoring, 48th EASD Annual Meeting

[8]

October, pp. 1-5, (2012)

[9]

Palmer A.J., Roze S., Valentine W.J., Et al., The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making, Curr Med Res Opin, 20, 1, pp. 5-26, (2004)

[10]

McEwan P., Foos V., Palmer J.L., Et al., Validation of the IMS CORE Diabetes Model, Value Health, 17, pp. 714-724, (2014)

← 1 2 3 4 →